scholarly journals Liquid biopsy approach to pancreatic cancer

2021 ◽  
Vol 13 (10) ◽  
pp. 1263-1287
Author(s):  
Sonia Perales ◽  
Carolina Torres ◽  
Cristina Jimenez-Luna ◽  
Jose Prados ◽  
Joaquina Martinez-Galan ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liquid Biopsy

scholarly journals Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1986
Author(s):  
Victoria Heredia-Soto ◽  
Nuria Rodríguez-Salas ◽  
Jaime Feliu
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Practice ◽  
Early Diagnosis ◽  
Minimally Invasive ◽  
Liquid Biopsy ◽  
Genetic Material ◽  
Current Status ◽  
Ductal Adenocarcinoma ◽  
Disease Monitoring ◽  
Global Status

Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to advance in the development of tools that help us in the early diagnosis, treatment selection, disease monitoring, evaluation of the response and prognosis. Liquid biopsy (LB), in its different modalities, represents a particularly interesting tool for these purposes, since it is a minimally invasive and risk-free procedure that can detect both the presence of genetic material from the tumor and circulating tumor cells (CTCs) in the blood and therefore distantly reflect the global status of the disease. In this work we review the current status of the main LB modalities (ctDNA, exosomes, CTCs and cfRNAs) for detecting and monitoring PDAC.

scholarly journals A liquid biopsy gene panel for pancreatic cancer detection

2017 ◽  
Vol 28 ◽  
pp. x9
Author(s):  
K. Kato ◽  
K. Ohkawa ◽  
R. Takada ◽  
H. Uehara ◽  
Y. Kukita ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Detection ◽  
Liquid Biopsy ◽  
Gene Panel

Exosomes as a platform for ‘liquid biopsy’ in pancreatic cancer

2017 ◽  
Vol 3 (1) ◽  
pp. 013005 ◽  
Author(s):  
Antonios Chronopoulos ◽  
Tyler J Lieberthal ◽  
Armando E del Río Hernández
Keyword(s):  
Pancreatic Cancer ◽  
Liquid Biopsy

scholarly journals Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers 2021, 13, 1612

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3687
Author(s):  
Julie Earl ◽  
Emma Barreto ◽  
María E. Castillo ◽  
Raquel Fuentes ◽  
Mercedes Rodríguez-Garrote ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Somatic Mutation ◽  
Liquid Biopsy ◽  
Clinical Analysis ◽  
Familial Pancreatic Cancer ◽  
Mutation Profiling

The authors wish to make the following corrections to this paper [...]

scholarly journals Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Brendan F. Miller ◽  
Hanna M. Petrykowska ◽  
Laura Elnitski
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Single Molecule ◽  
Peripheral Blood ◽  
Liquid Biopsy ◽  
Mutation Frequency ◽  
Cpg Island ◽  
Early Stage ◽  
Plasma Samples ◽  
Primary Tumors

AbstractOne epigenetic hallmark of many cancer types is differential DNA methylation occurring at multiple loci compared to normal tissue. Detection and assessment of the methylation state at a specific locus could be an effective cancer diagnostic. We assessed the effectiveness of hypermethylation at the CpG island of ZNF154, a previously reported multi-cancer specific signature for use in a blood-based cancer detection assay. To predict its effectiveness, we compared methylation levels of 3698 primary tumors encompassing 11 solid cancers, 724 controls, 2711 peripheral blood cell samples, and 350 noncancer disease tissues from publicly available methylation array datasets. We performed a single-molecule high-resolution DNA melt analysis on 71 plasma samples from cancer patients and 20 noncancer individuals to assess ZNF154 methylation as a candidate diagnostic metric in liquid biopsy and compared results to KRAS mutation frequency in the case of pancreatic carcinoma. We documented ZNF154 hypermethylation in early stage tumors, which did not increase in most noncancer disease or with respect to age or sex in peripheral blood cells, suggesting it is a promising target in liquid biopsy. ZNF154 cfDNA methylation discriminated cases from healthy donor plasma samples in minimal plasma volumes and outperformed KRAS mutation frequency in pancreatic cancer.

scholarly journals Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids

2016 ◽  
Vol 22 (25) ◽  
pp. 5627 ◽  
Author(s):  
Taisuke Imamura ◽  
Shuhei Komatsu ◽  
Daisuke Ichikawa ◽  
Tsutomu Kawaguchi ◽  
Mahito Miyamae ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Nucleic Acids ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy

LIQUID BIOPSY INDEXES AS PREDICTIVE MARKERS OF CHEMORADIOTHERAPY EFFICACY IN PATIENTS WITH PANCREATIC CANCER

2017 ◽  
Vol 63 (5) ◽  
pp. 738-742
Author(s):  
Sergey Ivanov ◽  
Luiza Korytova ◽  
Igor Ovchinnikov ◽  
Ye. Vlasova
Keyword(s):  
Pancreatic Cancer ◽  
Life Span ◽  
Total Dose ◽  
Liquid Biopsy ◽  
Stage Iv ◽  
Predictive Markers ◽  
Biochemical Index ◽  
Treatment Start ◽  
Dose Fraction ◽  
Fraction Dose

Patients with stage IV of pancreatic cancer were locally irradiated by 51 Gy total dose (fraction dose was 3 Gy). Gemcytabin, gemsar + carboplatin, or carboplatin + etoposid + 5-fluorouracil were intraarterially administered as chemotherapy preparations. DNA radiosensitivity biomarkers in patient blood were determined before the treatment start. There was revealed interrelation between value of biochemical index and life span patient. The DNA blood radiosensitivity index determinations are enabled to predict personally the results more success treatment in patients with pancreatic cancer after the use of abovementioned regimens of chemoradiotherapy.

Sign in / Sign up

Export Citation Format

Share Document